Another phase 1/2 NCT01994850 trial showed an ORR of 100% when combining BV with R‐CHP as first‐line therapy for CD30‐positive B‐cell lymphoma patients, with a CR rate of 86% and a 2‐year PFS and OS of 85% and 100%, respectively.112. This evidence concerns the gene TNFRSF8 and B-cell non-Hodgkin lymphoma.